-
1
-
-
33748116898
-
Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study
-
Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
-
(2006)
J Acquir Immune Defic Syndr
, vol.43
, pp. 27-34
-
-
Palella, F.J.1
Baker, R.K.2
Moorman, A.C.3
-
2
-
-
16444367183
-
Mortality trends: Toward a new definition of AIDS?
-
Highleyman L. Mortality trends: toward a new definition of AIDS? BETA. 2005;17(2):18-28.
-
(2005)
BETA
, vol.17
, Issue.2
, pp. 18-28
-
-
Highleyman, L.1
-
3
-
-
43749090365
-
Impact of lipoatrophy on quality of life in HIV patients receiving antiretroviral therapy (ART)
-
July 19-21, Sydney, Australia. Abstract
-
Rajagopalan R, Laitinen D, Dietz B. Impact of lipoatrophy on quality of life in HIV patients receiving antiretroviral therapy (ART). Adverse Drug Reaction and Lipodystrophy Workshop in HIV; July 19-21, 2007; Sydney, Australia. Abstract P-21.
-
(2007)
Adverse Drug Reaction and Lipodystrophy Workshop in HIV
-
-
Rajagopalan, R.1
Laitinen, D.2
Dietz, B.3
-
4
-
-
0036742741
-
Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients
-
Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413-417.
-
(2002)
AIDS Patient Care STDS
, vol.16
, pp. 413-417
-
-
Oette, M.1
Juretzko, P.2
Kroidl, A.3
-
5
-
-
25144459550
-
Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: Evaluation of accuracy and reproducibility
-
Yang Y, Paton NI. Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility. HIV Med. 2005;6:321-325.
-
(2005)
HIV Med
, vol.6
, pp. 321-325
-
-
Yang, Y.1
Paton, N.I.2
-
6
-
-
17544375309
-
Interventions for managing antiretroviral therapy-associated lipoatrophy
-
Sutinen J. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis. 2005;18:25-33.
-
(2005)
Curr Opin Infect Dis
, vol.18
, pp. 25-33
-
-
Sutinen, J.1
-
7
-
-
28344455060
-
Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients: Results from a cohort of 94 patients
-
February 8-11, San Francisco. Abstract 726
-
Lafaurie M, Dolivo M, Boulu D, et al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV-infected patients: results from a cohort of 94 patients. 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 726.
-
(2004)
11th Conference on Retroviruses and Opportunistic Infections
-
-
Lafaurie, M.1
Dolivo, M.2
Boulu, D.3
-
9
-
-
33745902508
-
Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: A review of the clinical studies
-
Barton SE, Engelhard P, Conant M. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies. Int J STD AIDS. 2006;17:429-435.
-
(2006)
Int J STD AIDS
, vol.17
, pp. 429-435
-
-
Barton, S.E.1
Engelhard, P.2
Conant, M.3
-
10
-
-
34547741214
-
Treatment for lipoatrophy: Facing the real costs
-
Margolis DM. Treatment for lipoatrophy: facing the real costs. AIDS. 2007;21:1819-1820.
-
(2007)
AIDS
, vol.21
, pp. 1819-1820
-
-
Margolis, D.M.1
-
11
-
-
33645376980
-
Correction options for lipoatrophy in HIV-infected patients
-
Engelhard P. Correction options for lipoatrophy in HIV-infected patients. AIDS Patient Care STDS. 2006;20:151-160.
-
(2006)
AIDS Patient Care STDS
, vol.20
, pp. 151-160
-
-
Engelhard, P.1
-
12
-
-
34548290415
-
Strategies in the treatment of HIV-1-associated adipose redistribution syndromes
-
del Mar Gutierrez M, Mateo G, Domingo P. Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opin Pharmacother. 2007;8:1871-1884.
-
(2007)
Expert Opin Pharmacother
, vol.8
, pp. 1871-1884
-
-
del Mar Gutierrez, M.1
Mateo, G.2
Domingo, P.3
-
13
-
-
18844428017
-
Therapeutic approaches to combating lipoatrophy: Do they work?
-
Martin A, Mallon PW. Therapeutic approaches to combating lipoatrophy: do they work? J Antimicrob Chemother. 2005;55:612-615.
-
(2005)
J Antimicrob Chemother
, vol.55
, pp. 612-615
-
-
Martin, A.1
Mallon, P.W.2
-
14
-
-
33644859584
-
HIV facial lipoatrophy: Causes and treatment options
-
Jones D. HIV facial lipoatrophy: causes and treatment options. Dermatol Surg. 2005;31(11 pt 2):1519-1529.
-
(2005)
Dermatol Surg
, vol.31
, Issue.11 PART 2
, pp. 1519-1529
-
-
Jones, D.1
-
15
-
-
6344282674
-
Editorial: The needs-based approach to quality of life assessment
-
McKenna SP, Doward LC. Editorial: the needs-based approach to quality of life assessment. Value Health. 2004;7(suppl 1):S1-S3.
-
(2004)
Value Health
, vol.7
, Issue.SUPPL. 1
-
-
McKenna, S.P.1
Doward, L.C.2
-
16
-
-
33646436423
-
Effect of antiretroviral therapy on the quality of patient's life
-
Cholewínska G. Effect of antiretroviral therapy on the quality of patient's life. HIV AIDS Rev. 2005;4:35-41.
-
(2005)
HIV AIDS Rev
, vol.4
, pp. 35-41
-
-
Cholewínska, G.1
-
18
-
-
22144486633
-
Relationship between lipoatrophy and quality of life
-
Echavez M, Horstman W. Relationship between lipoatrophy and quality of life. AIDS Reader. 2005;15:369-375.
-
(2005)
AIDS Reader
, vol.15
, pp. 369-375
-
-
Echavez, M.1
Horstman, W.2
-
19
-
-
6344253018
-
Defining patient-reported outcomes
-
Doward LC, McKenna SP. Defining patient-reported outcomes. Value Health. 2004;7(suppl 1):S4-S8.
-
(2004)
Value Health
, vol.7
, Issue.SUPPL. 1
-
-
Doward, L.C.1
McKenna, S.P.2
-
20
-
-
6344231646
-
Requirements for quality of life instruments in clinical research
-
Doward LC, Meads DM, Thorsen H. Requirements for quality of life instruments in clinical research. Value Health. 2004;7(suppl 1):S13-S16.
-
(2004)
Value Health
, vol.7
, Issue.SUPPL. 1
-
-
Doward, L.C.1
Meads, D.M.2
Thorsen, H.3
-
21
-
-
0037395720
-
A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals
-
Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect. 2003;79:137-141.
-
(2003)
Sex Transm Infect
, vol.79
, pp. 137-141
-
-
Power, R.1
Tate, H.L.2
McGill, S.M.3
Taylor, C.4
-
22
-
-
0033809393
-
Psychosocial impact of the lipodystrophy syndrome in HIV infection
-
Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546-550.
-
(2000)
AIDS Reader
, vol.10
, pp. 546-550
-
-
Collins, E.1
Wagner, C.2
Walmsley, S.3
-
23
-
-
33751093063
-
Impact of lipodystrophy on quality of life
-
July 9-14, Durban, South Africa. Abstract WePpB1381
-
Goetzenich A, Corzillius M, Mauss S, et al. Impact of lipodystrophy on quality of life. 13th International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePpB1381.
-
(2000)
13th International AIDS Conference
-
-
Goetzenich, A.1
Corzillius, M.2
Mauss, S.3
-
24
-
-
18844408365
-
The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults
-
Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res. 2005;14:981-990.
-
(2005)
Qual Life Res
, vol.14
, pp. 981-990
-
-
Burgoyne, R.1
Collins, E.2
Wagner, C.3
-
25
-
-
33748684776
-
Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution
-
Reynolds NR, Neidig JL, Wu AW, et al. Balancing disfigurement and fear of disease progression: patient perceptions of HIV body fat redistribution. AIDS Care. 2006;18:663-673.
-
(2006)
AIDS Care
, vol.18
, pp. 663-673
-
-
Reynolds, N.R.1
Neidig, J.L.2
Wu, A.W.3
-
26
-
-
27944493963
-
Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors
-
Santos CP, Felipe YX, Braga PE, et al. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005;19(suppl 4):S14-S21.
-
(2005)
AIDS
, vol.19
, Issue.SUPPL. 4
-
-
Santos, C.P.1
Felipe, Y.X.2
Braga, P.E.3
-
27
-
-
43749098455
-
Peripheral fat depletion (lipoatrophy) and other body shape changes - impact on psychosocial quality of life
-
July 9-14, Durban, South Africa. Abstract WePeD4566
-
Forrester J, Whittaker W, Workman C. Peripheral fat depletion (lipoatrophy) and other body shape changes - impact on psychosocial quality of life. 13th International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePeD4566.
-
(2000)
13th International AIDS Conference
-
-
Forrester, J.1
Whittaker, W.2
Workman, C.3
-
28
-
-
0037114879
-
Relationship between HAART adherence and adipose tissue alterations
-
Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S140-S144.
-
(2002)
J Acquir Immune Defic Syndr
, vol.31
, Issue.SUPPL. 3
-
-
Ammassari, A.1
Antinori, A.2
Cozzi-Lepri, A.3
-
29
-
-
0037111631
-
Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: Prevalence, associated factors, and psychological impact
-
Paton NI, Earnest A, Ng YM, et al. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis. 2002;35:1244-1249.
-
(2002)
Clin Infect Dis
, vol.35
, pp. 1244-1249
-
-
Paton, N.I.1
Earnest, A.2
Ng, Y.M.3
-
30
-
-
25144455962
-
Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS
-
Corless IB, Kirksey KM, Kemppainen J, et al. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS. 2005;19:577-586.
-
(2005)
AIDS Patient Care STDS
, vol.19
, pp. 577-586
-
-
Corless, I.B.1
Kirksey, K.M.2
Kemppainen, J.3
-
31
-
-
0003316261
-
The impact of patient perceptions of body shape changes and metabolic abnormalities on ART
-
July 9-14, Durban, South Africa. Abstract WePpB138
-
Kasper TB, Arboleda CH, Halpern MT. The impact of patient perceptions of body shape changes and metabolic abnormalities on ART. 13th International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePpB138.
-
(2000)
13th International AIDS Conference
-
-
Kasper, T.B.1
Arboleda, C.H.2
Halpern, M.T.3
-
32
-
-
36148946474
-
Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda
-
Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther. 2007;4:19.
-
(2007)
AIDS Res Ther
, vol.4
, pp. 19
-
-
Mutimura, E.1
Stewart, A.2
Crowther, N.J.3
-
33
-
-
12144287591
-
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA
-
Valantin M, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-2477.
-
(2003)
AIDS
, vol.17
, pp. 2471-2477
-
-
Valantin, M.1
Aubron-Olivier, C.2
Ghosn, J.3
-
34
-
-
10744229634
-
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial
-
Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429-438.
-
(2004)
Lancet
, vol.363
, pp. 429-438
-
-
Carr, A.1
Workman, C.2
Carey, D.3
-
35
-
-
0036190733
-
DAGNA Lipantiretoviral therapy study group. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment
-
Mauss S, Corzillius M, Wolf E, et al; DAGNA Lipantiretoviral therapy study group. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med. 2002;3:49-55.
-
(2002)
HIV Med
, vol.3
, pp. 49-55
-
-
Mauss, S.1
Corzillius, M.2
Wolf, E.3
-
36
-
-
43749117886
-
Psychological assessment of HIV-infected patients with facial lipoatrophy before and after reparatory treatment
-
July 11-16, Bangkok, Thailand. Abstract WePeB5930
-
Fumaz CR, Muñoz-Moreno JA, Ferrer MJ, et al. Psychological assessment of HIV-infected patients with facial lipoatrophy before and after reparatory treatment. 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WePeB5930.
-
(2004)
15th International AIDS Conference
-
-
Fumaz, C.R.1
Muñoz-Moreno, J.A.2
Ferrer, M.J.3
-
40
-
-
0030847865
-
Evidence for reliability, validity, and usefulness of Medical Outcomes Study HIV Health Survey (MOS-HIV)
-
Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity, and usefulness of Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
-
(1997)
Qual Life Res
, vol.6
, pp. 481-493
-
-
Wu, A.W.1
Revicki, D.A.2
Jacobson, D.3
Malitz, F.E.4
-
41
-
-
33846203789
-
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: A prospective study comparing autologous fat and synthetic substances
-
Negredo E, Higueras C, Adell X, et al. Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS. 2006;20:829-837.
-
(2006)
AIDS Patient Care STDS
, vol.20
, pp. 829-837
-
-
Negredo, E.1
Higueras, C.2
Adell, X.3
-
42
-
-
0037055028
-
Mitochondrial Toxicity (MITOX) study group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial
-
Carr A, Workman C, Smith DE, et al; Mitochondrial Toxicity (MITOX) study group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215.
-
(2002)
JAMA
, vol.288
, pp. 207-215
-
-
Carr, A.1
Workman, C.2
Smith, D.E.3
-
43
-
-
0025688231
-
EuroQol - a new facility for the measurement of health-related quality of life
-
The EuroQol Group
-
The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
-
(1990)
Health Policy
, vol.16
, pp. 199-208
-
-
-
44
-
-
0026667228
-
Validating the SF-36 health survey questionnaire: New outcome measure for primary care
-
Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160-164.
-
(1992)
BMJ
, vol.305
, pp. 160-164
-
-
Brazier, J.E.1
Harper, R.2
Jones, N.M.3
-
45
-
-
0027292883
-
Testing the validity of the EuroQoL and comparing it with the SF-36 health survey questionnaire
-
Brazier J, Jones N, Kind P. Testing the validity of the EuroQoL and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2:169-180.
-
(1993)
Qual Life Res
, vol.2
, pp. 169-180
-
-
Brazier, J.1
Jones, N.2
Kind, P.3
-
46
-
-
34248512901
-
Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients
-
Loutfy MR, Raboud JM, Antoniou T, et al. Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS. 2007;21:1147-1155.
-
(2007)
AIDS
, vol.21
, pp. 1147-1155
-
-
Loutfy, M.R.1
Raboud, J.M.2
Antoniou, T.3
-
47
-
-
0031051937
-
Dermatology quality of life scales - a measure of the impact of skin diseases
-
Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales - a measure of the impact of skin diseases. Br J Dermatol. 1997;136:202-206.
-
(1997)
Br J Dermatol
, vol.136
, pp. 202-206
-
-
Morgan, M.1
McCreedy, R.2
Simpson, J.3
Hay, R.J.4
-
48
-
-
0020527558
-
The hospital anxiety and depression scale
-
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
-
(1983)
Acta Psychiatr Scand
, vol.67
, pp. 361-370
-
-
Zigmond, A.S.1
Snaith, R.P.2
-
49
-
-
33645100143
-
Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy
-
Cattelan AM, Bauer U, Trevenzoli M, et al. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol. 2006;142:329-334.
-
(2006)
Arch Dermatol
, vol.142
, pp. 329-334
-
-
Cattelan, A.M.1
Bauer, U.2
Trevenzoli, M.3
-
50
-
-
1642524396
-
A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection
-
Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87.
-
(2004)
HIV Med
, vol.5
, pp. 82-87
-
-
Moyle, G.J.1
Lysakova, L.2
Brown, S.3
-
51
-
-
33750227103
-
-
Moyle GJ, Sabin CA, Cartledge J, et al; Rave (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
-
Moyle GJ, Sabin CA, Cartledge J, et al; Rave (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
-
-
-
-
52
-
-
15044346198
-
Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients
-
Lafaurie M, Dolivo M, Porcher R, et al. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:393-398.
-
(2005)
J Acquir Immune Defic Syndr
, vol.38
, pp. 393-398
-
-
Lafaurie, M.1
Dolivo, M.2
Porcher, R.3
-
53
-
-
0026877917
-
The MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection
-
Ware JE, Sherbourne CD. The MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
-
(1992)
Med Care
, vol.30
, pp. 473-483
-
-
Ware, J.E.1
Sherbourne, C.D.2
-
54
-
-
36549015755
-
Facial LipoAtrophy Study in HIV Investigators. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy
-
Carey DL, Baker D, Rogers GD, et al; Facial LipoAtrophy Study in HIV Investigators. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr. 2007;46:581-589.
-
(2007)
J Acquir Immune Defic Syndr
, vol.46
, pp. 581-589
-
-
Carey, D.L.1
Baker, D.2
Rogers, G.D.3
-
55
-
-
0029975592
-
The impact of human immunodeficiency virus (HIV) infection on quality of life in a multiracial South African population
-
O'Keefe EA, Wood R. The impact of human immunodeficiency virus (HIV) infection on quality of life in a multiracial South African population. Qual Life Res. 1996;5:275-280.
-
(1996)
Qual Life Res
, vol.5
, pp. 275-280
-
-
O'Keefe, E.A.1
Wood, R.2
-
57
-
-
11344275569
-
Safety and efficacy of intradermal poly-L-lactic acid (Sculptra) injections in patients with HIV-associated facial lipoatrophy
-
Abstract 56
-
Mest DR, Humble G. Safety and efficacy of intradermal poly-L-lactic acid (Sculptra) injections in patients with HIV-associated facial lipoatrophy. Antivir Ther. 2004;9:L36. Abstract 56.
-
(2004)
Antivir Ther
, vol.9
-
-
Mest, D.R.1
Humble, G.2
-
58
-
-
33750609380
-
Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience
-
Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg. 2006;32:1336-1345.
-
(2006)
Dermatol Surg
, vol.32
, pp. 1336-1345
-
-
Mest, D.R.1
Humble, G.2
-
59
-
-
34249658315
-
Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging
-
Hanke CW, Redbord KP. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol. 2007;6:123-128.
-
(2007)
J Drugs Dermatol
, vol.6
, pp. 123-128
-
-
Hanke, C.W.1
Redbord, K.P.2
-
60
-
-
0037183921
-
Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue
-
Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS. 2002;16:1985-1987.
-
(2002)
AIDS
, vol.16
, pp. 1985-1987
-
-
Levan, P.1
Nguyen, T.H.2
Lallemand, F.3
-
61
-
-
85011374820
-
Psychosocial adjustment to facial lipoatrophy in people with HIV
-
Abstract 34
-
O'Donovan CA, Hourihan M, Petrak J, Murphy M. Psychosocial adjustment to facial lipoatrophy in people with HIV. Antivir Ther. 2005;10:L24. Abstract 34.
-
(2005)
Antivir Ther
, vol.10
-
-
O'Donovan, C.A.1
Hourihan, M.2
Petrak, J.3
Murphy, M.4
-
62
-
-
84952922185
-
-
Rosenberg M. Society and the Adolescent Self-image. Princeton, NJ: Princeton University Press; 1965.
-
Rosenberg M. Society and the Adolescent Self-image. Princeton, NJ: Princeton University Press; 1965.
-
-
-
-
63
-
-
20344364086
-
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy
-
Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005;52:233-239.
-
(2005)
J Am Acad Dermatol
, vol.52
, pp. 233-239
-
-
Burgess, C.M.1
Quiroga, R.M.2
-
64
-
-
27144477778
-
Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique
-
Burnouf M, Buffet M, Schwarzinger M, et al. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique. Arch Dermatol. 2005;141:1220-1224.
-
(2005)
Arch Dermatol
, vol.141
, pp. 1220-1224
-
-
Burnouf, M.1
Buffet, M.2
Schwarzinger, M.3
-
65
-
-
43749116800
-
Intradermal polylactic acid (Newfill) for treatment of severe HIV-associated facial lipoatrophy
-
April 19-21, York, United Kingdom. Abstract O13
-
Day JN, Raabe A, Shiner AM, Wilkins EL. Intradermal polylactic acid (Newfill) for treatment of severe HIV-associated facial lipoatrophy. 8th Annual conference of the British HIV Association; April 19-21, 2002; York, United Kingdom. Abstract O13.
-
(2002)
8th Annual conference of the British HIV Association
-
-
Day, J.N.1
Raabe, A.2
Shiner, A.M.3
Wilkins, E.L.4
-
66
-
-
34247124454
-
Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy
-
Honda M, Yogi A, Ishizuka N, et al. Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy. Intern Med. 2007;46:359-362.
-
(2007)
Intern Med
, vol.46
, pp. 359-362
-
-
Honda, M.1
Yogi, A.2
Ishizuka, N.3
-
67
-
-
34249865891
-
A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy
-
Cavalcanti R, Raboud J, Shen S, et al. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis. 2007;195:1754-1761.
-
(2007)
J Infect Dis
, vol.195
, pp. 1754-1761
-
-
Cavalcanti, R.1
Raboud, J.2
Shen, S.3
-
68
-
-
31644438879
-
Appearance-related side effects of HIV-1 treatment
-
Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS. 2006;20:6-18.
-
(2006)
AIDS Patient Care STDS
, vol.20
, pp. 6-18
-
-
Hawkins, T.1
|